Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects

Petersen, Jens A; Kuntzer, Thierry; Fischer, Dirk; von der Hagen, Maja; Huebner, Angela; Kana, Veronika; Lobrinus, Johannes Alexander; Kress, Wolfram; Rushing, Elisabeth J; Sinnreich, Michael; Jung, Hans H

doi:10.1186/s12883-015-0449-3

Scientific article

English

Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects

ContributorsPetersen, Jens A; Kuntzer, Thierry; Fischer, Dirk; von der Hagen, Maja; Huebner, Angela; Kana, Veronika; Lobrinus, Johannes Alexander; Kress, Wolfram; Rushing, Elisabeth J; Sinnreich, Michael; Jung, Hans H

Published inBMC neurology, vol. 15, 182

Publication date2015

Abstract

Dysferlin is reduced in patients with limb girdle muscular dystrophy type 2B, Miyoshi myopathy, distal anterior compartment myopathy, and in certain Ethnic clusters.

Affiliation entities

Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie

Research groups

Métastases du foie (657)

Citation (ISO format)

PETERSEN, Jens A et al. Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects. In: BMC neurology, 2015, vol. 15, p. 182. doi: 10.1186/s12883-015-0449-3

Article (Accepted version)

CC BY

Identifiers

PID : unige:83967
DOI : 10.1186/s12883-015-0449-3
PMID : 26444858

Journal ISSN1471-2377

469views

137downloads

Creation01/26/2016 10:49:00 AM

First validation01/26/2016 10:49:00 AM

Update time03/15/2023 12:23:02 AM

Status update03/15/2023 12:23:02 AM

Last indexation10/31/2024 3:28:56 AM

Archive ouverte UNIGE

Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects

Dysferlin is reduced in patients with limb girdle muscular dystrophy type 2B, Miyoshi myopathy, distal anterior compartment myopathy, and in certain Ethnic clusters.

Technical informations